Monte Rosa Therapeutics Form 144 lists RSU and resale details

Monte Rosa Therapeutics Inc. notice of a proposed sale of Common shares under a Form 144, listing Rockefeller Capital Management as the broker and NASDAQ as the market.

Rhea-AI Filing Summary

Monte Rosa Therapeutics Inc. notice of a proposed sale of Common shares under a Form 144, listing Rockefeller Capital Management as the broker and NASDAQ as the market.

The excerpt shows a RSU stock award of 21,865 shares dated 01/02/2025 with a related date 01/02/2026. It also records recent dispositions by Markus Warmuth: an entry dated 03/02/2026 with $97,974.22 and a sale on 04/14/2026 of 8,000 shares for $141,124.80.

Insights

Corporate Governance Analyst

Form 144 lists a proposed resale of restricted/common shares and recent insider dispositions.

The filing names Rockefeller Capital Management as the broker and indicates transactions tied to awarded RSUs (21,865 shares, award date 01/02/2025 with a related date 01/02/2026). The listing of recent sales by Markus Warmuth provides transaction-level context for resale activity.

Cash‑flow treatment and total amount being offered are not detailed here; subsequent filings or trade confirmations would show timing and method. Future disclosures may clarify whether these are planned brokered resales or private dispositions.

Key Figures

RSU award: 21,865 shares Insider sale (04/14/2026): 8,000 shares Insider proceeds (03/02/2026): $97,974.22

3 metrics

RSU award 21,865 shares Stock award dated 01/02/2025 with related date 01/02/2026

Insider sale (04/14/2026) 8,000 shares Sale on 04/14/2026 for $141,124.80

Insider proceeds (03/02/2026) $97,974.22 Entry dated 03/02/2026 listed under securities sold during past 3 months

Key Terms

RSU, Form 144, Rockefeller Capital Management

3 terms

RSU financial

"RSU | 01/02/2025 | Stock Award | From Issuer | 21865"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rockefeller Capital Management other

"Common | Rockefeller Capital Management 500 Boylston Street"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Monte Rosa Therapeutics (GLUE) Form 144 disclose?

It discloses a proposed resale of Common shares and identifies Rockefeller Capital Management as the broker. The excerpt lists an RSU award of 21,865 shares and recent sales by Markus Warmuth on 03/02/2026 and 04/14/2026.

How many RSU shares are shown in the GLUE excerpt?

The excerpt shows an RSU stock award of 21,865 shares with an award date of 01/02/2025 and a related date of 01/02/2026. This line is labeled as a compensation award.

What recent sales by insiders are listed in the Form 144 excerpt for GLUE?

The excerpt records a transaction on 03/02/2026 with $97,974.22 and a sale on 04/14/2026 of 8,000 shares for $141,124.80, both attributed to Markus Warmuth in the table.

Does the excerpt state how the resale will be executed for GLUE shares?

The excerpt names Rockefeller Capital Management as the broker and lists NASDAQ as the market. It does not specify the precise distribution methods or timing for the proposed resale in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:53 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855643
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Monte Rosa Therapeutics, Inc.
SEC File Number	001-40522
Address of Issuer	321 HARRISON AVENUE SUITE 900 BOSTON MASSACHUSETTS 02118
Phone	617-949-2643
Name of Person for Whose Account the Securities are To Be Sold	Warmuth Markus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Capital Management 500 Boylston Street Suite 1300 Boston MA 02116	5467	103446628.00	84382573	05/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
RSU	01/02/2025	Stock Award	From Issuer			21865	01/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	03/02/2026	5466	97974.22
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	04/14/2026	8000	141124.80

144: Remarks and Signature

Remarks
Date of Notice	05/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Warmuth Markus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)